文献速递类风湿关节炎

根据3个月应答水平预测类风湿关节炎6个月治疗目标的实现

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.
PubMed 文献 · RMD Open · 2018-10-26

基于NOR-DMARD研究2000至2012年纳入的1610例类风湿关节炎(RA)患者,采用诊断试验方法分析3个月应答与6个月治疗目标之间的关联。结果显示,3个月未达到SDAI 50%改善会显著降低6个月缓解的可能性(阴性似然比0.15-0.36),而3个月达到SDAI 85%应答显著提高6个月缓解的可能性(阳性似然比6.56)。基线疾病活动度较高者若3个月未达到SDAI 70%应答,6个月缓解可能性很低。

要点

  • 3个月未达SDAI 50%改善者6个月缓解可能性显著降低。
  • 3个月达SDAI 85%应答者6个月缓解可能性显著增加。
  • 基线高疾病活动度者3个月应答要求更高(SDAI 70%)。

核心结论

  • 3个月疾病活动度改善水平可帮助临床医生在达标治疗策略中决定继续还是调整正在进行的治疗,以6个月内达到缓解或低疾病活动度为目标。
  • 3个月所需改善水平随基线疾病活动度不同而变化。

研究设计与样本

  • 研究纳入NOR-DMARD研究中2000至2012年间入组的1610例类风湿关节炎患者。
  • 对全部患者进行分析,并按基线疾病活动度、病程或甲氨蝶呤/肿瘤坏死因子抑制剂治疗进行亚组重复分析。
  • 采用诊断试验方法探讨3个月应答与6个月结局之间的关联。

主要发现

  • 3个月未达到SDAI 50%改善在所有亚组中均显著降低6个月达到缓解的可能性(阴性似然比0.15-0.36)。
  • 开始治疗时高疾病活动度患者若3个月未达到SDAI 70%应答,则很可能无法达到缓解(阴性似然比0.25,阴性预测值0.98)。
  • 3个月达到SDAI 85%重大应答显著增加6个月达到缓解的可能性(阳性似然比6.56)。

关键数值与推荐

  • 3个月SDAI 50%改善为预测6个月缓解的关键阈值,未达到时阴性似然比0.15-0.36。
  • 基线高疾病活动度者3个月SDAI 70%应答对应阴性似然比0.25、阴性预测值0.98。
  • 3个月SDAI 85%应答对应阳性似然比6.56。

临床怎么用

  • 临床可在3个月时评估SDAI改善水平,结合基线疾病活动度判断6个月达标的可能性。
  • 对3个月未达相应SDAI改善阈值的患者,可考虑调整正在进行的治疗以追求6个月内达标。

局限性

  • 原文未报告研究局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: When initiating a new therapy in patients with rheumatoid arthritis (RA), current treatment recommendations suggest escalating therapy in case of poor clinical improvement by 3 months or if the treatment target has not been reached by 6 months. We investigated which disease activity improvement levels at 3 months predicted achievement of the treatment targets at 6 months in a real-life clinical setting. METHODS: We included 1610 patients with RA enrolled in the NOR-DMARD study between 2000 and 2012. Analyses were performed for the total group of patients and repeated for subgroups stratified by baseline disease activity, disease duration or treatment with methotrexate or a tumour necrosis factor inhibitor. We used a diagnostic test approach to explore the associations between 3-month response and 6-month outcome. RESULTS: Not achieving 50% improvement in Simplified Disease Activity Index (SDAI) by 3 months significantly decreased the likelihood of reaching remission at 6 months in all subgroups (negative likelihood ratios (LRs-) 0.15-0.36). Patients with high disease activity when initiating treatment were likely to fail reaching remission if they achieved less than SDAI 70% response by 3 months (LR- 0.25 and negative predictive value 0.98). Achieving a major response (SDAI 85%) at 3 months significantly increased the likelihood of reaching remission at 6 months (LRs+ 6.56). CONCLUSION: Levels of 3-month disease activity improvement can inform clinicians when deciding to continue or adjust ongoing therapy in a treat-to-target strategy aiming for remission or low disease activity within 6 months. The required levels of 3-month improvement varied with baseline disease activity.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Norvang V, Sexton J, Kristianslund EK, et al. Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. RMD Open. 2018. PMID: 30488000. doi:10.1136/rmdopen-2018-000773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。